Compare NGNE & EVH Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | NGNE | EVH |
|---|---|---|
| Founded | 2003 | 2011 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Other Consumer Services |
| Sector | Health Care | Consumer Discretionary |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 498.2M | 469.0M |
| IPO Year | 2014 | 2015 |
| Metric | NGNE | EVH |
|---|---|---|
| Price | $35.40 | $5.58 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 7 | 15 |
| Target Price | ★ $63.57 | $7.93 |
| AVG Volume (30 Days) | 219.9K | ★ 2.5M |
| Earning Date | 05-08-2026 | 05-07-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 0.93 | N/A |
| EPS | N/A | ★ N/A |
| Revenue | N/A | ★ $907,957,000.00 |
| Revenue This Year | N/A | $33.89 |
| Revenue Next Year | N/A | $15.84 |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $15.93 | $2.10 |
| 52 Week High | $37.27 | $11.81 |
| Indicator | NGNE | EVH |
|---|---|---|
| Relative Strength Index (RSI) | 68.81 | 65.82 |
| Support Level | $19.27 | $3.67 |
| Resistance Level | $36.37 | $8.30 |
| Average True Range (ATR) | 2.05 | 0.35 |
| MACD | 0.39 | 0.07 |
| Stochastic Oscillator | 95.22 | 80.50 |
Neurogene Inc is a clinical-stage biotechnology company committed to overcoming the limitations of neurological diseases into treatable conditions, by harnessing its proprietary transgene regulation technology, EXACT(Expression Attenuation via Construct Tuning). It is building a differentiated product portfolio of genetic medicines for rare neurological diseases with high unmet needs. The drug candidates in the company's product pipeline include NGN-401, which is in development for the treatment of Rett syndrome, using its EXACT platform, and NGN-101, a non-EXACT, conventional gene therapy development candidate for the treatment of CLN5 Batten disease, designed to deliver the CLN5 gene and packaged in an AAV9 capsid.
Evolent Health Inc is engaged in healthcare delivery and payment. The company supports health systems and physician organizations in their migration toward value-based care and population health management. It provides specialty care management services in oncology, cardiology, musculoskeletal markets and holistic total cost of care management along with an integrated platform for health plan administration and value-based business infrastructure under one go to market package. The solutions provided by the company includes: Oncology, Cardiology, Musculoskeletal, Administrative Services, Advanced Illness, Genetic Testing, Physical Medicine, Radiology, and Surgical Management.